TGEN Tecogen Inc

Targeted Genetics to Present at the 7th Annual Meeting of the American Society of Gene Therapy Presentations Demonstrate Broad Potential of Company's AAV Technology SEATTLE, May 26 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation's technology assets will be highlighted in 12 presentations during the 7th Annual Meeting of the American Society of Gene Therapy. The meeting will take place June 2 - June 6 in Minneapolis, MN. Presentations will focus on the Company's core product development programs and the utility of adeno-associated virus (AAV) vector delivery technology. Targeted Genetics currently has three AAV-based product candidates in clinical development, including an AIDS vaccine and treatments for cystic fibrosis and rheumatoid arthritis. Presentations are as follows: Rheumatoid Arthritis Abstract #99 Long-Term Expression of Soluble TNFR:Fc Protein Following Multiple Administrations of AAV-TNFR:Fc Vector Pseudotyped with Capsids of Alternate Serotypes. Thursday, June 3. Poster presentation. Workshop #224 Musculo-Skeletal: Designing and Planning Clinical Trials for Musculo-Skeletal Diseases. AAV-TNFR:Fc Gene Therapy for Inflammatory Joint Diseases. Thursday, June 3. Oral presentation. Abstract #880 Suppression of Inflammation in a Rat Model of Arthritis Following Intramuscular Administration of AAV-TNFR:Fc Vector Pseudotyped with AAV Type 1 Capsid. Saturday, June 5. Poster presentation. Abstract #881 Preclinical Safety Assessment of Intra-Articular Administration of rAAV-humanTNFR:Fc in Rats in Support of a Phase I Arthritis Trial. Saturday, June 5. Poster presentation. Cystic Fibrosis Abstract #489 Comparison of AAV2 and AAV2/5 CFTR Vectors in the Lungs of Cynomolgus Macaques. Friday, June 4. Poster presentation. Abstract #756 Distinct Classes of Proteasome-Modulating Agents Cooperatively Augment Recombinant Adeno-Associated Virus Type 2 and Type 5-mediated Transduction from the Apical Surface of Human Airway Epithelia. Saturday, June 5. Poster presentation. Abstract #760 Dual Therapeutic Utility of Proteasome Modulating Agents for Pharmico-Gene Therapy of the Cystic Fibrosis Airway. Saturday, June 5. Poster presentation. AIDS Vaccine Scientific Symposium #401 Gene-Based Vaccines: Clinical Applications of Gene-Based Vaccines and Immunotherapeutics (Biodefense, Vaccines, Cancer). Saturday, June 5. Oral presentation. Core Technology: Adeno-Associated Virus (AAV) Vectors Abstract #12 A New Class of Hybrid Adeno-Associated Viral Vectors with Non-Homologous ITRs Improves Directional Recombination and Dual-Vector Reconstitution of Large Transgenes. Thursday, June 3. Oral presentation. Abstract #346 Characterization of Adeno-Associated Virus Sequences in Human Tissues. Friday, June 4. Oral presentation. Abstract #744 Genetic Structure of Adeno-Associated Virus DNA in Human Tissues. Saturday, June 5. Poster presentation. Abstract #754 Intracellular Trafficking Patterns of rAAV2 Demonstrate Significant Cell-Type Specificity. Saturday, June 5. Poster presentation. For more information about the 7th Annual Meeting of the American Society of Gene Therapy, please refer to http://www.asgt.org/. Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies, as well as a promising body of technology for cellular therapy under development by its subsidiary company, CellExSys. For more information about the Company, visit its website at http://www.targetedgenetics.com/. This release contains forward-looking statements regarding our regulatory filings, research programs, clinical trials, product development and other statements about our plans, objectives, intentions and expectations. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, the timing, nature and results of our research and our clinical trials, our ability to recruit and enroll suitable trial participants, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property, and our ability to raise capital when needed, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations. DATASOURCE: Targeted Genetics Corporation CONTACT: Courtney Self of Targeted Genetics Corporation, +1-206-521-7392 Web site: http://www.asgt.org/ Web site: http://www.targetedgenetics.com/

Copyright